John N. Allan, MD, on Research Coming Out of ASH for CLL

In an interview with CancerNetwork®, John N. Allan, MD, assistant professor of medicine in the Division of Hematology and Medical Oncology at Weill Cornell Medicine, discussed the latest research coming out of the 62nd American Society of Hematology (ASH) Annual Meeting for patients with chronic lymphocytic leukemia (CLL).

Transcription:

Yeah, so one of the big things I'm most interested about this year's ASH is as when I was reviewing the abstracts was seeing, how much data is going to be emerging in terms of the combinations and really seeing how deep can these responses go? How durable are these responses after maximal therapy, so to speak, and stopping or fixed durations of therapies and so, so that'll be really important to keep an eye on. As well as, you know, we're getting better at understanding resistant mechanisms to these targeted agents, so, looking at how patients relapse, how do they respond to new therapies after they've relapsed, especially if they've had treatment holidays. So, these are things that will be at this year's ASH and looking forward to digesting that data.